TMPRSS2-ERG Fusion Prostate Cancer Prevalence Linked To PSA Density And Histologic Features In Multicenter US Prostate Biopsy Cohort
July 1st, 2008
ORLANDO, FL (UroToday.com) - In a certain proportion of prostate cancers, the prostate-specific androgen-regulated gene TMPRSS2 is fused with the gene for the transcription factor ERG.This gene fusion product may have prognostic significance in men with the CaP; however, the exact prevalence of the genetic abnormality is debated.
Posted in Uncategorized | No Comments »
ORLANDO, FL (UroToday.com) - Although reduction in prostate cancer mortality rates is important, it is necessary to consider the effects of prostate cancer screening and treatment on patient quality of life. Potential gains in survival could be more than offset decrements in quality of life that may result from diagnosis and treatment.
ORLANDO, FL (UroToday.com) - Pathologic stage T0 (pT0) rates following radical cystectomy (RC) alone range from 10-15%. The pT0 rate increases in patients that have received neoadjuvant platinum-based chemotherapy.
At the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology’s 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO) held last week in Houston, Texas, The GI Company reported secondary endpoints relating to Oral Mucositis Assessment Scale (OMAS) scores from the Company’s Phase II clinical study, designed to evaluate the safety and efficacy of its lead clinical compound, Intestinal Trefoil Factor (rhITF) Oral Spray, in development for oral mucositis.
Percutaneous radiofrequency ablation - a minimally invasive treatment technique that heats and destroys cancer cells - achieves a high rate of sustained complete responses in selected patients with lung tumours, according to results from the first prospective study of patients treated with technique.
Smoke-free policies reduce the exposure of both adults and children, reduce the prevalence of smoking in adults and reduce the risk of heart disease related to smoke exposure. A resulting reduction in the lung cancer burden may well occur as a result of these policies, but relevant evidence will only become available some time in the future.
A new targeted drug therapy developed at The Institute of Cancer Research is showing positive results in killing tumour cells of some common cancers in the laboratory, according to a study published in Clinical
ORLANDO, FL (UroToday.com) - Dr. E. David Crawford presented information on challenges facing clinical trials from SWOG, ECOG and CALGB. Patient accrual for clinical trials is only 2-3%. Innumerable layers of rules and regulations have been created with numerous layers that increase costs and delays. He applauded prevention trials such as PCPT, SELECT, Toremifene for PIN and REDUCE.
To examine the results of open partial nephrectomy (OPN) over a 15-year period in a large UK teaching hospital and to compare results with other series including minimally invasive techniques, as nephron-sparing techniques are still under-utilized in the surgical treatment of renal carcinoma.